Article Details

The competitive landscape of neoantigen-targeting therapeutics in oncology

Retrieved on: 2021-07-08 12:56:15

Tags for this article:

Click the tags to see associated articles and topics

The competitive landscape of neoantigen-targeting therapeutics in oncology. View article details on hiswai:

Excerpt

The four molecules expected to launch first are Roche's autogene cevumeran, Gritstone Bio's GRANITE-001, Achilles' ATL001 and Genocea ...

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up